Back to Search
Start Over
1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II).
- Source :
-
Annals of Oncology . 2023 Supplement 2, Vol. 34, pS754-S754. 1p. - Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 34
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 173099104
- Full Text :
- https://doi.org/10.1016/j.annonc.2023.09.2346